An important breakthrough in the understanding of BCR-ABL–negative MPN has been accomplished by the discovery of the JAK2V617F mutation, underlying the role of pathologic JAK/STAT signaling in MPN [1,2]. This evidence concerns the gene ABL1 and myeloproliferative disorder.